Malignant spinal cord compression (MSCC) is one of the most disabling complications of cancer metastasis. Patients with endometrial carcinoma rarely present spinal cord or cauda equina compression secondary to epidural metastasis. It is an oncological emergency requiring prompt diagnosis and treatment. However, the early signs and symptoms of compression can be overlooked. It usually occurs months or even years after the diagnosis of the primary disease. Here we report a case of endometrial cancer that presented MSCC because of thoracic vertebral bone metastasis and underwent vertebrectomy and radiotherapy.

A 65-year old postmenopausal woman, gravida 3, para 3, presented with vaginal bleeding and lower abdominal tumor and visited a local clinic, and was referred to our department. Ultrasound scans revealed a large pelvic mass with a diameter of 15 cm. Cytological test of uterine cervix was negative. That of the endometrium was not possible. Abdominal CT scans revealed a huge pelvic mass partially carcified (Figure 1). No lymphadenopathy or ascites was noticed. Magnetic resonance imaging (MRI) revealed a heterogeneous solid tumor (Figure 2). Chest CT showed multiple lung metastases that seemed as metastases of the pelvic tumor (Figure 3). Serum level of LDH was elevated to 1519U/l, whereas other tumor markers were within normal range. Uterine leiomyosarcoma was suspected. The patient was admitted and total abdominal hysterectomy and bilateral salpingo-oophorectomy were carried out (Figure 4). Histopathological studies revealed mixed carcinoma (small cell carcinoma and endometrioid adenocarcinoma) with cervical invasion and peritoneal dissemination (Figure 5). Four days after surgery, she presented with upper abdominal pain and back pain. And 8 days after surgery, she presented with cystoplegia and paraplegia of lower extremities. MRI revealed bone metastasis with destruction of the eighth thoracic vertebral body as the sites of metastasis (Figure 6). She was diagnosed as having MSCC. Following administration of dexamethasone (6.6 mg, 20 mg and 13.2 mg, consecutively), she underwent vertebrectomy and posterior spinal fusion, and postoperative radiation therapy was performed to total of 20 Gray in 4 fractions. The histopathological studies revealed malignant cells. Although artifacts made detailed histopathological diagnosis difficult, we clinically diagnosed this lesion as metastasis from endometrial cancer. However, her symptoms were not improved. Although she received two courses of systemic chemotherapy consisting of paclitaxel and carboplatin (180 mg/m² and

AUC = 6, respectively), CT scan of the chest revealed new lung metastatic lesion, and she selected the best supportive care. She died 4 months after hysterectomy.

Although recent progress of chemotherapy has made the lives of cancer patients longer, the rate of bone metastasis is increasing accordingly. Bone is the third most frequent site of cancer metastasis next to lung and liver.

Breast cancer is the most common origin of bone metastasis, followed by lung cancer and uterine cancer. Approximately 70% of cancer patients have metastasis at their death [1]. The spine is the most common osseous site for metastatic disease and may be involved up to 40% of the patients with cancer, and 5% to 10% of all cancer patients may develop epidural spinal cord compression [2]. And 10% to 20% of patients with bony spinal disease develop symptomatic spinal cord compression [3]. The definition of MSCC is compression of the dural sac and its contents (spinal cord and/or cauda equine) by extradural tumor mass [4]. Endometrial cancer metastasizes to the bone less frequently than cervical cancer. Rome et al. stated in his review of 11 comprehensive series containing 1075 cases with all types of malignancy, that there were 35 cases of primary gynecologic malignancy and 3 cases were uterine corpus cancer. They reported that MSCC patients showed following symptoms: 1) back pain; 2) root pain; 3) motor disturbance; 4) sensory disturbance; 5) disturbance of bladder and/or bowel function [5]. Gilbert et al. reported that thoracic region was involved in 68% of metastatic extradural tumors, and pain was the primary symptom of 96% of the patients, while motor or sensory deficits were found in 82% of them [6]. The present case showed all those symptoms that Rome et al. stated and was diagnosed with MSCC. Although MSCC usually appear several months or years after the diagnosis of the primary disease, this patient presented it very early, as 1 week after operation.

As for diagnosis, Loblaw et al. reported that the sensitivity and specificity for MRI range from 0.44 to 0.93 and 0.90 to 0.98, respectively, and that the sensitivity and specificity for myelography range from 0.71 to 0.97 and 0.88 to 1.00, respectively. They concluded that MRI is the preferred imaging technique [4].

The management of MSCC consists of surgery, radiation and chemotherapy. And good evidence supports the use of steroids in patients with newly diagnosed MSCC. Dexamethasone is the most widely used steroid, although the optimal dose is controversial [7]. Radiotherapy has been the primary therapy for metastatic spinal disease. Until the mid-1980s, posterior decompressive laminectomy was regarded as the only surgical option, but its efficacy had been disappointing. However, surgery that decompresses the spinal cord circumferentially, followed by reconstruction and immediate stabilization has proven effective. Klimo et al. [8] reviewed 24 surgical articles (999 patients) and 4 radiation articles (543 patients). Overall ambulatory success rates for surgery and radiation were 85% and 64% respectively, and the cumulative rescue rates for the surgical and radiation literature were 0.58 and 0.26 respectively. They concluded that all patients diagnosed with metastatic spinal disease should be evaluated for surgery as a primary treatment modality. However, once neurological symptoms appear, they usually progress promptly, and the quality of life of the patient is harmed seriously. Currently, the results of treatment of neurological compression due to gynecologic malignancies are still unsatisfactory. As prevention is important, early diagnosis and good treatment of the primary disease are mandatory.